Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02586389 |
Recruitment Status :
Recruiting
First Posted : October 26, 2015
Last Update Posted : August 9, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Non-hematologic Cancer |
Study Type : | Observational |
Estimated Enrollment : | 3000 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Collection of Whole Blood and Tissue Specimens From Patients Diagnosed With Non-Hematologic Cancer for Use in Development of a Noninvasive Liquid Biopsy Assay to Determine the Tumor Genomic Profile in Circulating Cell-Free Tumor DNA |
Study Start Date : | October 2015 |
Estimated Primary Completion Date : | October 2025 |
Estimated Study Completion Date : | October 2025 |
Group/Cohort |
---|
Non-hematological Cancer Cohort
Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
|
- biospecimen sample collection for liquid biopsy assay development [ Time Frame: After cancer diagnosis through 5 years of standard of care follow-up visits ]Analysis of circulating tumor DNA (ctDNA) in whole blood will be compared to baseline tumor DNA for concordance of mutations related to cancer.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Subject is 18 years of age or older;
- Subject is willing to provide written informed consent;
-
Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;
- residual tumor tissue available for testing by the Sponsor; or
- genomic profiling results from an IVD or LDT assay performed on tumor biopsy tissue; or
- an invasive procedure (biopsy, surgery) scheduled following the Baseline Visit from which residual tumor tissue can be available for testing by the Sponsor.
- Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits.
Exclusion Criteria:
- Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.
- Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.
- Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).
- Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02586389
Contact: Graham McLennan | (858) 202-9162 | gmclennan@sequenom.com |
United States, California | |
Compassionate Care Research Group, Inc. | Recruiting |
Riverside, California, United States, 92501 | |
Contact: Corina King, CCRP |
Study Director: | Sue Beruti, MD | Sequenom, Inc. |
Responsible Party: | Sequenom, Inc. |
ClinicalTrials.gov Identifier: | NCT02586389 |
Other Study ID Numbers: |
SQNM-CA-101 |
First Posted: | October 26, 2015 Key Record Dates |
Last Update Posted: | August 9, 2023 |
Last Verified: | August 2023 |